Sitagliptin

Rediff.com » News » Sitagliptin

News for Sitagliptin

Business

Diabetes Drug Price Drops 90%

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.......

Price relief for diabetes patients as drugs go off patent

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category......

Sun Pharma, Merck to market diabetes drugs

Sun Pharmaceutical Industries Ltd and MSD in India said they have entered into a partnership to market diabetes drugs Sitagliptin and Sitaglipitin plus Metformin in the Indian market.Under the......

Prices of key diabetes, cancer drugs may drop by 25%

A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments. The next......

Merck & Co wins injunction against Indian firm over diabetes drugs

MSD, a unit of US drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs......

Sitagliptin

News for Sitagliptin

Diabetes Drug Price Drops 90%

Price relief for diabetes patients as drugs go off patent

Sun Pharma, Merck to market diabetes drugs

Prices of key diabetes, cancer drugs may drop by 25%

Merck & Co wins injunction against Indian firm over diabetes drugs

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS